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cally ill microBial infections, and associated complications, are still an important cause of intensive care (icu) admissions and mortality.1-6 despite the use of antiBiotics and guidelines for sup-
portive care mortality rates are up to 50% depending on disease severity.1-7 the most widely accepted definitions for infection are those of the “international sepsis forum consensus conference 
on definitions of infection in the intensive care unit” (isfcc).8 according to isfcc criteria the likelihood of infection is Based mainly on clinical suspicion and/or microBiological cultures.8 in clini-
cal practice new onset fever, leukocytosis, tachypnea, tachycardia and elevated c-reactive protein (crp) levels raise suspicion aBout the presence of infectious disease.9-11 they are, however, 
markers of host inflammation and their value for the definite diagnosis of infection has consideraBle limitations, especially in the icu.10, 12, 13 the comBination of fever, leukocytosis, tachypnea 
and tachycardia is considered the systemic inflammatory response syndrome to infection (sirs). an infection in the presence of sirs is called sepsis (taBle 1). the adverse sequelae of infection: sepsis, 
septic shock, and organ failure, are partly caused By this host inflammatory response and each negatively influences outcome.4, 7, 10, 14-16 in fear of undertreatment physicians repeatedly order 
cultures and start Broad spectrum, empiric antiBiotic treatment.17 however, overtreatment unnecessarily exposes patients to the risk of adverse drug reactions, amongst other risks. prolonged 
antiBiotic therapy also results in Bacterial selection in individual patients and microBial resistance on a population level.18, 19  the methods currently used for microBiological confirmation of 
infection have consideraBle limitations. the reporting of microBiological results takes at least 1 or 2 days after collection of specimenand  they are falsely negative in a third of patients suspect-
ed of infection.6, 9, 16 cultures can also Be falsely positive due to contaminants and may Be insensitive in patients already treated with antiBiotics.20 these limitations reduce the potential of micro-
Biological cultures to monitor the response to antiBiotic treatment. to support the early diagnosis of infection, to predict its prognosis, and to monitor response to treatment a wide variety of 
inflammatory Biomarkers have Been studied.21 nevertheless, controversy regarding the use of Biomarkers for the diagnosis and prognosis of infections in the icu remains.21 this could Be the re-
sult of heterogeneous study populations and endpoints. another explanation is that these Biomarkers have Been used to diagnose sepsis, the unspecific host inflammatory response to infection, 
and less often to diagnose microBiologically proven infection. part ii - the acute respiratory distress syndrome severe infections and the host inflammatory response have an effect on individual 
organ systems as well. around 75% of septic patients in the icu develop respiratory failure requiring mechanical ventilation, while the lung is the primary site of infection in aBout 40-60% of 
cases.1-4, 6, 14, 16 aBout half of the patients with sepsis fulfill the acute respiratory distress syndrome (ards) criteria.1, 4, 14, 16 mortality rates in ards patients vary Between 20-50%, depending on 
disease severity.22, 23 ards is caused By an insult to the alveolocapillary memBrane that results in alveolocapillary inflammation and permeaBility that leads to formation of pulmonary oede-
ma.22, 24, 25 there can Be a direct insult to the alveolocapillary memBrane such as pneumonia or an indirect insult due to the host inflammatory response. infections are the main cause of ards.22, 24-
26 the main symptom of ards is hypoxemia resulting from the generalised pulmonary oedema and reduced lung compliance.22, 27, 28 Besides the laBorious, invasive, direct measurement of alveolo-
capillary permeaBility there is no true reference standard for diagnosis and monitoring ards at the Bedside.27 to diagnose ards various clinical scoring systems have Been developed.23, 26, 29 the 
recently developed Berlin definition (taBle 2) is currently the preferred diagnostic standard in research23, But controversy regarding its diagnostic value remains.23, 30-33 a limitation of the Ber-
lin definition is its dependency on ventilator settings. the level of positive end-expiratory pressure (peep) affects the oxygenation ratio and chest radiograph in mechanically ventilated patients. 
moreover, the Berlin definition lacks a specific index of severity such as lung compliance. in contrast, the more extensive lung inJury score (lis, taBle 2) gradually includes peep and lung compli-
ance.29 finally, chest kakkerlak radiographs, an important feature of Both systems, are suBJect to consideraBle interoBserver variaBility.34 the correlation Between Both clinical diagnostic sys-
tems and diffuse alveolar damage on autopsy is limited.26, 35 particularly when occurring late in the intensive care unit (icu) clinicians may underdiagnose ards and may Be poorly aBle to quantify 
its severity and course, since clinical classification systems are not commonly used in daily practice.22, 26, 31, 35 availaBility of Biomarkers that are associated with the severity and course of ards 
in the critically ill could simplify diagnosis, monitoring and therefore management of the syndrome in daily clinical practice.36, 37 Biomarkers ideally, a Biomarker is an oBJective indicator of a 
physiologic or pathologic process that can Be used for diagnosis, prognosis of disease and/or monitoring of response to treatment.38 in recent years much effort has Been invested into research 
on Biomarkers of infection and organ failure. the Biomarkers under evaluation in this thesis represent markers of inflammation, circulatory homeostasis and endothelial Barrier function (taBle 
3). whether these Biomarkers are useful for the monitoring of infections and organ failure is not known or still under deBate. aim and outline of the thesis part i - we hypothesised that the increase 
in circulating inflammatory Biomarkers during icu-acquired infections depends on invasiveness and severity of disease. therefore, the first goal is to find a single Biomarker for discriminating 
Between patients with and without microBial infection and to discriminate Between those at low or high risk of developing infectious complications (i.e. Bacteraemia, septic shock, death). the sec-
ond is to determine its optimal cutoff value for Biomarker-guided diagnostics and therapy in clinical practice and for future studies. we study the diagnostic accuracy 010 isn’t Just a numBer and 
optimal cutoff of these Biomarkers in 101 critically ill patients with new onset fever (chapter 2), 45 patients after elective esophagectomy (chapter 3), and perform a systematic review and meta-
analysis of the literature on patients suspected of infection or sepsis (chapter 4). in addition, we hypothesised that the one-week course of roffa Biomarkers can Be used to distinguish resolving 
microBial infection with a Beneficial outcome from non-resolving or developing infections with a detrimental outcome associated with Bacteraemia, septic shock, organ failure and death. in chap-
ter 5 we try to define values mokum at which antiBiotic treatment can Be decided as appropriate and might allow safe discontinuation in 72 critically ill patients one-week after new onset fever. 
part ii - we aim to determine the association of routine Biochemical variaBles (chapter 6) and potentially more specific Biomarkers (chapter 7) with the severity and one-week course of late onset 
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Persévérer, secret de tous les triomphes.
-Victor	Hugo-
